Efficacy and Toxicity of Fifth-line Nivolumab in a 15-Year-Old Girl With Metastatic Juvenile Renal Cell Carcinoma

J Pediatr Hematol Oncol. 2018 Apr;40(3):251-252. doi: 10.1097/MPH.0000000000001086.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents, Immunological / therapeutic use
  • Carcinoma, Renal Cell / drug therapy*
  • Female
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Neoplasm Recurrence, Local / drug therapy*
  • Nivolumab / therapeutic use*
  • Salvage Therapy / methods

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab